Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Prazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 5/20 | 0.72 |
| ▸ | GABRA5 known ✓ | P31644 | 5/20 | 0.72 |
| ▸ | GABRA2 known ✓ | P47869 | 5/20 | 0.72 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.72 |
| ▸ | GABRA3 known ✓ | P34903 | 3/20 | 0.72 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.57 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.57 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.53 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.53 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.53 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.53 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.53 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.53 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.53 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.53 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.72 |
| ▸ | BRD4 | O60885 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prazepam SCHEMBL78272 | 0.88 | OPRK1 (0.69) | OPRK1GABRA1GABRA5GABRA2GABRB2 | |
| Prazepam SCHEMBL29565880 | 0.88 | OPRK1 (0.69) | OPRK1GABRA1GABRA5GABRA2GABRB2 | |
| Halazepam SCHEMBL28086105 | 0.86 | OPRK1 (0.77) | OPRK1GABRA1GABRA5GABRA2HPGD | |
| Alprazolam SCHEMBL8398 | 0.85 | GABRA1 (1.00) | OPRK1GABRA1GABRA5GABRA2HPGD | |
| Alprazolam SCHEMBL16922178 | 0.85 | GABRA1 (1.00) | OPRK1GABRA1GABRA5GABRA2HPGD | |
| Alprazolam SCHEMBL5480614 | 0.85 | GABRA1 (1.00) | OPRK1GABRA1GABRA5GABRA2HPGD | |
| Alprazolam SCHEMBL29381667 | 0.85 | GABRA1 (1.00) | OPRK1GABRA1GABRA5GABRA2HPGD | |
| Alprazolam SCHEMBL2420072 | 0.84 | GABRA1 (0.82) | OPRK1GABRA1GABRA5GABRA2HPGD | |
| Alprazolam SCHEMBL22527891 | 0.84 | GABRA1 (0.98) | OPRK1GABRA1GABRA5GABRA2HPGD | |
| Alprazolam SCHEMBL28964138 | 0.84 | GABRA1 (0.98) | OPRK1GABRA1GABRA5GABRA2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240123219-A1 | STIMULATION DESIGN FOR NEUROMODULATION | ADVANCED NEUROMODULATION SYSTEMS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11883648-B2 | Stimulation design for neuromodulation | ADVANCED NEUROMODULATION SYSTEMS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20190192852-A1 | STIMULATION DESIGN FOR NEUROMODULATION | ADVANCED NEUROMODULATION SYSTEMS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20170368339-A1 | NEW STIMULATION DESIGN FOR NEUROMODULATION | DE RIDDER DIRK (NZ) | 2017-12-28 | — | — | US | disclosed |
| US-9764135-B2 | Stimulation design for neuromodulation | ADVANCED NEUROMODULATION SYSTEMS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| CN-103717597-B | Heterocyclic compounds as kinase inhibitors | 原真股份有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-103492389-B | Pyrazolo [4,3-d] pyrimidine as inhibitors of kinases | 原真股份有限公司 | 2016-09-14 | — | — | CN | disclosed |
| US-9358393-B1 | Stimulation methods and systems for treating an auditory dysfunction | LOZANO ANDRES M (CA) | 2016-06-07 | — | — | US | disclosed |
| US-20160022168-A1 | BRAIN STATE DEPENDENT THERAPY FOR IMPROVED NEURAL TRAINING AND REHABILITATION | UNIVERSITY OF LETHBRIDGE (CA) | 2016-01-28 | — | — | US | disclosed |
| US-20150088212-A1 | STIMULATION DESIGN FOR NEUROMODULATION | ADVANCED NEUROMODULATION SYS (US) | 2015-03-26 | — | — | US | disclosed |
| US-20060116742-A1 | Spinal cord stimulation to treat auditory dysfunction | ADVANCED NEUROMODULATION SYSTEMS, INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2006057734-A1 | NEW STIMULATION DESIGN FOR NEUROMODULATION | ADVANCED NEUROMODULATION SYSTEMS, INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060100671-A1 | Stimulation of the amygdalohippocampal complex to treat neurological conditions | ADVANCED NEUROMODULATION SYSTEMS, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006047291-A2 | SPINAL CORD STIMULATION TO TREAT AUDITORY DYSFUNCTION | ADVANCED NEUROMODULATION SYSTEMS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006047265-A1 | STIMULATION OF THE AMYGDALOPHIPPOCAMPAL COMPLEX TO TREAT NEUROLOGICAL CONDITIONS | ADVANCED NEUROMODULATION SYSTEMS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006047264-A1 | PERIPHERAL NERVE STIMULATION TO TREAT AUDITORY DYSFUNCTION | ADVANCED NEUROMODULATION SYSTEMS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060095090-A1 | Peripheral nerve stimulation to treat auditory dysfunction | ADVANCED NEUROMODULATION SYSTEMS, INC. | 2006-05-04 | — | — | US | disclosed |
| US-20060095088-A1 | New stimulation design for neuromodulation | ADVANCED NEUROMODULATION SYSTEMS, INC. | 2006-05-04 | — | — | US | disclosed |
| US-20060064138-A1 | Method of treating mood disorders and/or anxiety disorders by brain stimulation | UNIVERSITY HEALTH NETWORK (CA) | 2006-03-23 | — | — | US | disclosed |
| WO-2005107858-A1 | METHOD OF TREATING MOOD DISORDERS AND/OR ANXIETY DISORDERS BY BRAIN STIMULATION | ADVANCED NEUROMODULATION SYSTEMS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |